Sanofi (SNY) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sanofi’s Sarclisa received a positive recommendation from the EMA’s CHMP for treating newly diagnosed multiple myeloma patients ineligible for stem cell transplants. This recommendation follows the successful results of the IMROZ phase 3 study, which demonstrated significant improvement in progression-free survival when Sarclisa was combined with VRd therapy. The approval would mark Sarclisa as the first anti-CD38 therapy available in this combination for such patients in the EU.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- New AI Push Proves Little Help to BlackBerry (TSE:BB)
- Shareholder Alert for iLearningEngines Holdings (NASDAQ:AILE)
- 3 Penny Stocks to Watch Now, 11/19/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
